Home » Regeneron’s Arcalyst Gout Drug Gets July PDUFA Target
Regeneron’s Arcalyst Gout Drug Gets July PDUFA Target
The FDA has set a July 30, 2012, user fee action goal date to review Regeneron’s sBLA for interleukin-1 inhibitor Arcalyst to treat gout flare-ups.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May